I just think that if you are going to release results why not say “on average patients that received rexlemestrocel had an improved ejection fraction from 28% to 45% rather than saying “12 months least squared was 5.0” it seems pretty ambiguous and neither you or I understand what that means
Ann: Rexlemestrocel-L Improves LVEF, Preceding Reduction in MACE, page-140
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.03 |
Change
0.005(0.49%) |
Mkt cap ! $1.170B | |||
| Open | High | Low | Value | Volume |
| $1.02 | $1.04 | $1.02 | $1.407M | 1.371M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 18 | 214781 | $1.02 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.03 | 18999 | 9 |
View Market Depth
| Last trade - 12.28pm 01/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |